News
-
-
-
PRESS RELEASE
MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe
MindMaze Therapeutics enrolls first patients in SwissNeuroRehab study to advance at-home reimbursement strategy in Europe, aiming to extend patient access from inpatient care to home-based rehabilitation -
-
REGULATED PRESS RELEASE
BIOPHYTIS REPORTS ITS PROVISIONAL FINANCIAL RESULTS AND PROVIDES ITS STRATEGIC OUTLOOK
Biophytis reports provisional financial results for fiscal year 2025 and strategic outlook, including milestones in sarcopenia and obesity programs, engagement with scientific community, and financial restructuring -
-
-
-
PRESS RELEASE
Onco-Innovations Announces Term Sheet for Notional CAD$5 Million Performance-Based Funding Arrangement and Amendments to Previously Announced Financing
Onco-Innovations Limited announces non-brokered private placement financing for CAD$5,000,000 with institutional investors. Offering consists of 6,764,070 units at CAD$0.7392/unit. Expected closing on July 15, 2026 -
PRESS RELEASE
Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010
Onco-Innovations announces polymer process development and analytical characterization activities for ONC010 nanoparticle inhibitor in collaboration with Nanosoft, strengthening future GMP manufacturing and clinical development
